Deficiency is rare. Cosmetic megadoses add nothing more; it is better to cover it through diet.
Possible improvement in fragile nails.
It only helps if there is a real deficiency, which is uncommon.
High doses alter laboratory results and can lead to erroneous diagnoses.
⏱ 3 min read
Biotin, also known as vitamin B7 or vitamin H, is a water-soluble B-group vitamin whose biological role is to serve as a cofactor for five mitochondrial and cytosolic carboxylases involved in fatty acid metabolism, gluconeogenesis, branched-chain amino acid catabolism, and essential fatty acid synthesis; these biochemical functions explain why severe biotin deficiency, though rare, produces a complex clinical picture with seborrheic dermatitis, alopecia, glossitis, irritability, depression, and, in pediatric cases due to disorders of biotin metabolism, significant neurological impairment.
Despite its well-defined biochemical profile, biotin has achieved enormous commercial popularity in the hair, skin, and nails supplement market (with typical commercial doses of 5,000-10,000 micrograms daily, amounts thousands of times higher than the recommended daily intake of 30 micrograms), a popularity that is not supported by solid clinical evidence for people with normal biotin status, but rather by an extrapolation from documented deficiency cases to the general population, a failed logic that clinical research has repeatedly refuted.
In people without biotin deficiency (the majority), there is no robust clinical evidence that high-dose supplementation improves hair growth, skin quality, or nail strength; several systematic reviews conclude that the available studies are methodologically weak, frequently industry-sponsored, and that the benefit observed in small studies is not replicable in large, well-designed cohorts.
In people with documented biotin deficiency or idiopathic onychodystrophy, several small studies have indeed shown significant improvements in nail thickness and reduced brittleness at doses of 2,500-10,000 micrograms daily for 3-6 months, a specific indication with clinical support that justifies use in properly selected patients.
In biotinidase deficiency (an inherited metabolic disorder detected in newborn screening in many countries) and in multiple carboxylase deficiency, high-dose biotin supplementation (10-20 milligrams daily) is the treatment of choice and prevents the characteristic neurological and dermatological deterioration; this clear, well-established clinical indication has no parallel with population-wide cosmetic use.
A clinically relevant complication of biotin megadoses is interference with immunoassays based on the biotin-streptavidin interaction, widely used to measure thyroid hormones, cardiac troponin, gonadotropins, vitamin D, and other parameters; high doses of biotin can produce falsely elevated or decreased results depending on the assay configuration, errors that have led to erroneous diagnoses of hyperthyroidism, nonexistent heart attacks, and other clinically serious situations; guidelines recommend stopping biotin at least 48-72 hours before any blood test.
Nutritional doses are 30 micrograms daily in adults; for onychodystrophy or alopecia with documented deficiency, 2,500-5,000 micrograms daily for 3-6 months; for disorders of biotin metabolism, specific doses set by the specialist; commercial megadoses of 10,000 micrograms daily provide no additional benefit in people without a deficiency and multiply the risk of analytical interference.
Generally very well tolerated even at high doses (no significant toxicities have been described); the most important clinical consideration is the immunoassay interference discussed above, which has produced serious erroneous diagnoses and must be actively communicated to the laboratory and the treating physician; prolonged high-dose use without a specific indication probably represents more of an unnecessary expense and a risk of analytical interference than a real benefit for most people.
Information, not medical advice. Scientific evidence reflects the quality of the studies.